1. Market Research
  2. > Pharmaceutical Market Trends
  3. > New Zealand Pharmaceuticals and Healthcare Report Q1 2017

New Zealand Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 70 pages

Includes 3 FREE quarterly updates


BMI View:

Multinational drugmakers seeking to commercialise their innovative treatments in New Zealand will continue to face challenges from the Pharmaceutical Management Agency. While the agency has played a pivotal role in ensuring the sustainability of the system, this has come at the expense of the number of novel treatments available to patients - 180 new treatments were funded in the last 10 years, which falls significantly short of the level in other developed markets. While acknowledged by the agency, innovation remains secondary to cost, and to demands that multinational pharmaceutical firms deliver treatments with expenditure savings in addition to stronger healthcare outcomes.

Headline Expenditure Forecasts



- Pharmaceuticals: NZD1.42bn (USD1.2bn) in 2015 to NZD1.44bn (USD976mn) in 2016; 1.2% in local currency terms and -2.8% in US dollar terms. Slight downward in its US dollar value is due to currency fluctuations of the New Zealand dollar.

- Healthcare: NZD27.4bn (USD19.1bn) in 2015 to NZD28.4bn (USD19.03bn) in 2016; 3.6% in local currency terms and -0.5% in US dollar terms. Downward revision in the US dollar value due to currency effects. In BMI’s Q1 2017 Pharmaceutical Risk/Reward Index (RRI), New Zealand has climbed up one place from its Q216 position, coming in at ninth out of 19 markets. With a score of 51.0 out of 100, the country is now ranked below the regional average of 51.2. A strong and predictable environment of low operating risks are weighed down by a small market and low potential for growth relative to other markets in the region.

Table Of Contents

New Zealand Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (New Zealand 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 15
Prescription Drug Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 19
Generic Drug Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 21
OTC Drug Market Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2014-2020) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (New Zealand 2014-2020) 25
Industry Risk Reward Index 26
Asia Pacific Risk/Reward Index 26
New Zealand Risk/Reward Index 32
Rewards 32
Risks 32
Regulatory Review 34
Regulatory Development 34
Intellectual Property Issues 34
Pricing and Reimbursement Regime 35
Table: Factors For Consideration 37
Market Overview 38
Healthcare Sector 38
Table: Healthcare Resources (New Zealand 2010-2015) 40
Table: Healthcare Activity (New Zealand 2010-2015) 40
Table: Healthcare Personnel (New Zealand 2010-2015) 40
Research and Development 41
Clinical Trials 42
Epidemiology 44
Competitive Landscape 47
Research-Based Industry 47
Table: Multinational Market Activity 48
Pharmaceutical Distribution 48
Pharmaceutical Retail Sector 49
Company Profile 51
Douglas Pharmaceuticals 51
New Zealand Pharmaceuticals 54
Pfizer New Zealand 57
Demographic Forecast 59
Table: Population Headline Indicators (New Zealand 1990-2025) 60
Table: Key Population Ratios (New Zealand 1990-2025) 60
Table: Urban/Rural Population and Life Expectancy (New Zealand 1990-2025) 61
Table: Population By Age Group (New Zealand 1990-2025) 61
Table: Population By Age Group % (New Zealand 1990-2025) 62
Glossary 64
Methodology 66
Pharmaceutical Expenditure Forecast Model 66
Healthcare Expenditure Forecast Model 66
Notes On Methodology 67
Risk/Reward Index Methodology 68
Index Overview 69
Table: Pharmaceutical Risk/Reward Index Indicators 69
Indicator Weightings 70

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.